Moorestown, NJ, November 23, 2015 --(PR.com
)-- CareKinesis, Inc. Chief Information Officer, Joe Filippoli
, MBA, announced today that the CareKinesis proprietary medication decision-support and e-prescribing platform, EireneRxCS
, has been approved for the electronic prescribing of controlled substances
as a result of receiving Drug Enforcement Administration (DEA) certification. InfoGard Laboratories, Inc., a DEA-Approved Certifying Organization, completed a successful audit and verification report that the CareKinesis EireneRxCS application meets all applicable requirements of the mandatory 21 Code of Federal Regulations, Subpart C, for an EPCS Prescription Application.
“We are delighted to receive DEA approval for EPCS,” said Filippoli. “Being able to include e-prescribing for controlled substances will go a long way to serving client and patient needs more effectively and efficiently.”
EireneRxCS is now a certified feature of the CareKinesis electronic Medication Risk Mitigation platform™
, which provides prescribers with patented, first of its kind, clinical decision-support components, including both evidence-based and patient-specific data, at the point of care. This cloud-based platform, connecting CareKinesis clinical pharmacists with client physicians and nurses in real time, is a comprehensive e-prescribing solution coupled with medication decision-support tools for use at the point of prescribing.
CareKinesis partners with health care organizations to provide personalized medication therapy management and prescription fulfillment services for clients with high-risk patient populations. The results are enhanced medication-related outcomes, overall cost savings and greater operational efficiency.
CareKinesis is the first national provider of personalized medication risk mitigation technology and services. It is a member of the Tabula Rasa HealthCare® family of companies, a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk